Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 9,144 Shares of Stock

Posted by Tammy Falkenburg on Apr 22nd, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 9,144 shares of the stock in a transaction dated Thursday, April 17th. The stock was sold at an average price of $11.78, for a total transaction of $107,716.32. Following the completion of the transaction, the insider now directly owns 3,068,072 shares of the company’s stock, valued at approximately $36,141,888.16. The trade was a 0.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, April 14th, Saba Capital Management, L.P. sold 15,400 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.67, for a total transaction of $179,718.00.
On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.14, for a total transaction of $335,937.84.
On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total value of $79,705.73.
On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total transaction of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total transaction of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.03, for a total transaction of $25,899.38.

Abrdn Life Sciences Investors Stock Performance

Shares of NYSE HQL opened at $11.76 on Tuesday. Abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $15.90. The firm has a 50 day moving average of $12.74 and a 200 day moving average of $13.67.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were paid a $0.47 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 annualized dividend and a dividend yield of 15.99%.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BankPlus Trust Department bought a new position in shares of Abrdn Life Sciences Investors in the fourth quarter worth about $28,000. Steward Partners Investment Advisory LLC increased its holdings in Abrdn Life Sciences Investors by 379.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock worth $64,000 after acquiring an additional 3,847 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in Abrdn Life Sciences Investors in the 1st quarter worth approximately $131,000. Landscape Capital Management L.L.C. bought a new stake in Abrdn Life Sciences Investors during the 4th quarter worth approximately $154,000. Finally, Kingswood Wealth Advisors LLC purchased a new position in Abrdn Life Sciences Investors during the fourth quarter valued at approximately $160,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

Abrdn Life Sciences Investors Company Profile

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.